Rare diseases require better intelligence, not just broader access.
Rare and ultra-rare diseases are often difficult to identify, diagnose, map and connect to the right clinical or therapeutic pathways. For biotech companies, this creates a major challenge: relevant patients may exist, experienced physicians may be treating them and clinical data may already be available — but the information is often fragmented across institutions, specialties, patient journeys, laboratory signals and real-world clinical experience. Pharma²⁸ helps turn that fragmented landscape into actionable rare disease intelligence.
Rare Disease Intelligence is the structured combination of medical expertise, curated scientific evidence, clinical and laboratory data interpretation, physician insight, patient-population mapping and AI-enabled data infrastructure.
The goal is to support better strategic decisions for rare disease therapies across international markets.
Pharma²⁸ applies this intelligence to help biotech companies better understand:
Where relevant patients may be concentrated
Across institutions and regions.
Which physicians and centers have the right disease expertise
Trusted specialist networks.
What clinical and laboratory patterns may indicate potential disease clusters
Diagnostic signal detection.
What evidence already exists in real-world clinical settings
Institutional and academic knowledge.
Which markets may offer meaningful clinical, regulatory and access opportunities
Strategic prioritization.
How patient identification and evidence generation can support responsible development
Ethical, credible pathways.
Rare disease opportunity assessment cannot rely only on population size or traditional market assumptions.
It requires the ability to interpret clinical signals, diagnostic pathways, specialist networks, institutional experience and fragmented real-world data.
Pharma²⁸ integrates these inputs to support:
Disease landscape mapping
Structured view of what is known.
Patient identification strategy
Where relevant patients may be found.
Diagnostic compatibility assessment
Clinical and laboratory patterns.
Cohort and center-of-excellence mapping
Physicians and institutions with credibility.
Evidence and literature mapping
Real-world and academic evidence.
Clinical feasibility analysis
Realistic pathways for programs.
Real-world evidence planning
Data supporting responsible decisions.
Physician and investigator engagement
Clinical credibility at the core.
Market-entry and access prioritization
Where opportunity is clinically aligned.
This allows biotech companies to evaluate not only whether a market is large, but whether it is clinically relevant, operationally feasible and strategically aligned with the therapy.
We focus on rare and ultra-rare diseases where scientific innovation, unmet medical need and international access opportunities intersect.
Our areas of interest include advanced pulmonary diseases, interstitial lung disease, genetic and metabolic disorders, neuromuscular conditions, pediatric rare diseases and other high-need therapeutic areas where targeted therapies may benefit from stronger global development pathways.
Brazil offers a rare combination of scale, clinical depth, academic medicine, experienced investigators, public-health infrastructure and significant unmet need.
But these strengths are often underused because the system is complex and fragmented. Relevant patients may be treated across different centers, physicians may hold deep disease-specific knowledge and real-world clinical information may exist without being structured in a way that is useful for biotech development decisions.
Pharma²⁸ helps make Brazil scientifically legible. By combining local medical insight, institutional relationships, disease-area expertise and AI-enabled data infrastructure, Pharma²⁸ supports a more structured understanding of where rare disease opportunities may exist and how they can be responsibly activated.
For biotech companies, rare disease intelligence can support multiple strategic questions:
Is Brazil relevant for this therapy?
Clinical, regulatory and access alignment.
Are there meaningful patient cohorts?
Where and how they can be identified.
Which physicians and centers should be engaged first?
Credibility and disease-area expertise.
What local evidence could support development or access?
Real-world experience and institutional data.
Could Brazil support real-world evidence generation?
Longitudinal, structured evidence.
Could Brazil support early access, clinical collaboration or regulatory development?
Responsible pathways aligned with need.
What would a responsible market-entry pathway look like?
From assessment to activation.
Pharma²⁸'s intelligence model is not technology alone.
Rare diseases require human clinical judgment, specialist interpretation and local medical credibility. AI-enabled infrastructure can help organize, compare, prioritize and interpret complex information — but the value comes from combining data with experienced physicians, researchers, institutions and strategic market understanding.
This human-plus-data model allows Pharma²⁸ to support biotech partners with intelligence that is clinically grounded, strategically useful and oriented toward real-world execution.
The purpose of rare disease intelligence is not simply to identify commercial opportunities.
It is to help align biotech innovation with real unmet medical need, credible clinical pathways, responsible evidence generation and improved patient access.
Pharma²⁸ supports rare disease programs where scientific innovation, patient need, physician expertise and international access opportunities intersect.
If your company is developing a therapy for a rare or ultra-rare disease, Pharma²⁸ can help assess whether Brazil or other international markets may offer relevant patient populations, clinical expertise, evidence-generation opportunities or strategic access pathways.
We help turn fragmented rare disease information into a clearer path for clinical validation, patient identification, real-world evidence and responsible international growth.
Let's connect.
If you are exploring international opportunities for a rare disease therapy, clinical program, data initiative or strategic partnership, we would welcome the opportunity to connect.